Croda International's latest narrative update leaves its estimated fair value largely intact at about £34.46 per share, even as the discount rate edges up to roughly 7.91%. This subtle shift reflects a market that is cautiously rewarding improving sentiment while still pricing in execution and growth risks flagged by both bullish and bearish research. Stay tuned to learn how investors can better track these incremental recalibrations in expectations as the story continues to evolve.

Stay updated as the Fair Value for Croda International shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Croda International.

???? Bullish Takeaways

Berenberg remains the clearest bull, reiterating a Buy rating and lifting its target to £33.00 from £31.00. This signals confidence in Croda International's execution quality and medium term growth prospects despite earlier volatility.

Barclays upgraded the shares to Overweight from Equal Weight, arguing that commoditization concerns may be overstated and that activist pressure could become a positive catalyst for value realization relative to current valuation.

Across more neutral houses, Deutsche Bank and Morgan Stanley both nudged targets higher (to £31.00 and £30.50 respectively) while staying Hold or Equal Weight. This suggests that better cost control and improved transparency are being acknowledged, but that a good portion of upside may already be reflected in the price.

???? Bearish Takeaways

Citi trimmed its target to £30.50 from £33.00 while maintaining a Neutral stance. This underscores persistent concerns that near term risks around delivery on growth and margin ambitions could cap further multiple expansion.

Even where price targets are rising, the prevalence of Hold and Equal Weight ratings at Deutsche Bank and Morgan Stanley highlights ongoing reservations around valuation. Analysts caution that much of the anticipated improvement in execution and growth momentum may already be priced in.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Croda International reiterated its full year 2025 guidance, confirming expectations for group adjusted profit before tax at constant currency, signaling management confidence in the current trading trajectory.

The company guided that Q4 2025 absolute sales will be seasonally lower than in the first three quarters, as customers typically manage working capital into year end. This frames the expected slowdown as a normal calendar effect rather than a structural setback.

Croda expects to deliver £265m to £295m of group adjusted profit before tax for fiscal 2025 at constant currency, supported by year to date sales growth and cost savings, even with the anticipated seasonal dip in Q4 sales.

Fair Value: Unchanged at approximately £34.46 per share, indicating a stable intrinsic value assessment despite other minor model adjustments.

Discount Rate: Risen slightly from about 7.89% to 7.91%, implying a marginally higher required return and modestly more conservative risk assumptions.

Revenue Growth: Effectively unchanged at around 4.76%, suggesting no material revision to the long term top line growth outlook.

Net Profit Margin: Stable at roughly 13.06%, reflecting consistent expectations for medium term profitability levels.

Future P/E: Edged up slightly from around 24.19x to 24.21x, which points to a barely higher implied valuation multiple on forward earnings.

Narratives are investor written stories that link what a company does to what its numbers could look like tomorrow. On Simply Wall St’s Community pages, millions of investors use Narratives to connect Croda International’s strategy to forecasts for revenue, earnings and margins, then translate that into an estimated fair value they can compare with today’s share price. Because Narratives update dynamically as fresh news, guidance or earnings arrive, they give investors a simple, accessible way to decide if and when it might be time to buy or sell.

Head over to the Simply Wall St Community and follow the Narrative on Croda International to stay on top of how this story evolves:

How activist pressure and management’s efficiency program reshape margins and justify a fair value near £34.46 per share.

Whether expansion into high growth emerging markets and sustainable, bio based chemistry can deliver the forecast approximately 5% annual revenue growth and margin recovery.

How risks like pricing pressure, inventories and restructuring could derail the path to analyst expectations and alter the gap between fair value and today’s price.

Read the original Narrative in full here: CRDA, Activist Pressure Will Drive A Reappraisal Of Margin Resilience.

Curious how numbers become stories that shape markets? Explore Community Narratives

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CRDA.L.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com